We acted as advisor to Keensight Capital in its acquisition of a majority stake in Biovian Oy alongside the founders and the managers of Biovian and Edmond de Rothschild Equity Strategies (ERES) funds. Our Private Equity, Tax & Structuring, and Banking & Finance services advised Keensight Capital on all relevant legal, tax, structuring and financing aspects of the transaction.
Founded in 2003, Biovian is a leading European GMP (Good Manufacturing Practice) contract development and manufacturing organisation (CDmO) of biopharmaceuticals, providing manufacturing and development services from early stage to finished product. The company provides services to approximately 30 customers, including international biotech and biopharma companies from the E.U., U.S. and South Korea.
Keensight Capital is one of the leading European growth buyout firms, having almost 20 years of experience in investing for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million. Keensight Capital has strong expertise in the sectors of internet & information technology and healthcare & wellbeing, and in particular the pharma industry and the CDmO sector.
